Ingalls Health System to join University of Chicago Medicine health system

The University of Chicago Medicine and Ingalls Health System have agreed to pursue a combined integrated health delivery system. Once the deal is final, Ingalls Health System will join the University of Chicago Medicine health network.

"Ingalls is pursuing a relationship that will combine the resources of the leading integrated health delivery system in Chicago's Southland with one of the nation's leading academic medical institutions," Eugene Feingold, chair of the Ingalls Health System board of directors, said in a statement. "The University of Chicago Medicine shares our commitment to quality and vision for health care in the South Suburbs. We remain dedicated to providing the personalized care that our community has come to expect from Ingalls."

"Our collective patients and communities will benefit from the complementary services and greater options,” Kenneth S. Polonsky, MD, executive vice president of medical affairs and dean of the biological sciences division at the University of Chicago, said in the same statement.

Ingalls Health System searched for a system to partner with for seven months before making its decision.

"We're pleased that our patients will have access to the expertise of one of the best academic medical centers in the country," Kurt Johnson, Ingalls Health System president and CEO, said in the statement. "Through this partnership, Ingalls will be able to invest in our facilities and enhance our technologies at an accelerated pace, which will help us continue our focus on providing innovative services and a strong regional network of top-rated outpatient services close to home."

The deal is expected to be final sometime in 2016.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.